Table 2.

Univariable and multivariable analysis for time to earliest major coronary events.

Variable	Univariable Cox Regression Analysis			Cox Multivariable Regression
	HR	95% CI	p-Value	HR	95% CI	p-Value
Sex, Male vs. Female	0.778	0.174–3.476	0.742
Age, ≥65 vs. <65	1.394	0.483–4.023	0.539
ECOG, 1–2 vs. 0	0.754	0.264–2.151	0.597
Smoking History, Yes vs. No	0.693	0.240–1.997	0.497
BMI, kg/m2, ≥30 vs. <30	1.290	0.452–3.681	0.634
History of CAD, Yes vs. No	1.735	0.483–6.232	0.398
History of Hyperlipidemia, Yes vs. No	9.748	1.275–74.532	0.028	10.522	1.373–80.621	0.023
History of Hypertension, Yes vs. No	4.247	0.950–18.991	0.058
History of Diabetes, Yes vs. No	0.853	0.238–3.060	0.808
Tumor Location, Upper/Middle vs. Distal/GEJ	2.767	0.768–9.956	0.119
Pathology, SCC vs. Adenocarcinoma	3.889	1.216–12.436	0.022
Clinical Stage, III vs. I/II	1.190	0.397–3.564	0.756
Induction Chemotherapy, Yes vs. No	0.705	0.221–2.247	0.554
Surgery, Yes vs. No	0.477	0.166–1.368	0.168
Radiotherapy Technology, IMRT vs. PBT	1.817	0.507–6.516	0.360
PTV, ≥600 cc vs. <600 cc	1.051	0.368–2.998	0.926
Platin-based Chemotherapy, Yes vs. No	1.349	0.473–3.849	0.576
LAD, V30Gy ≥ 10% vs. <10%	3.101	0.972–9.895	0.056	3.589	1.124–11.462	0.031

Abbreviations: CI, confidence interval; HR, hazard ratio; ECOG, Eastern Cooperative Oncology Group; BMI, body mass index; CAD, coronary artery disease; GEJ, gastroesophageal junction; SCC, squamous cell carcinoma; IMRT, intensity-modulated radiation therapy; PBT, proton beam therapy; PTV, Planning Target Volume; LAD, left anterior descending coronary artery.